Current live cold-adapted influenza vaccine producing in Russia contains A(H1N1), A(H3N2) and B vaccine strains prepared using A/Leningrad/134/17/57(H2N2) and B/USSR/60/69 master-strains. Vaccine strains are annually renewed in accordance to WHO recommendations. Live influenza vaccine is used for children 3-14 years old, adults and elderly. Live influenza vaccine is active in stimulating serum, local and cellular immunity. It's high immunogenicity and protective rate was proved in a number of double-blind placebo-controlled field trials according to WHO collaborative programm.

Scheeme of development of reassortant vaccine strain for live cold-adapted influenza vaccine vir-epidemic strain ca-cold-adapted master-strain rec-reassortant vaccine strain